Cingulate Appoints New CMO and CSO, Adds to Board
Ticker: CINGW · Form: 8-K · Filed: Sep 12, 2024 · CIK: 1862150
| Field | Detail |
|---|---|
| Company | Cingulate Inc. (CINGW) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $503,000, $424,000, $350,000, $1.45 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-appointment, executive-appointment
Related Tickers: CING
TL;DR
Cingulate beefs up exec team with new CMO/CSO, both now on the board.
AI Summary
On September 9, 2024, Cingulate Inc. announced the appointment of Dr. David M. Bear as Chief Medical Officer and Dr. Robert J. T. Miller as Chief Scientific Officer. The company also reported the election of Dr. Bear and Dr. Miller to its Board of Directors. These appointments are effective immediately.
Why It Matters
The appointment of experienced medical and scientific leaders signals a strategic move by Cingulate to bolster its research and development capabilities, potentially impacting its drug development pipeline.
Risk Assessment
Risk Level: medium — The appointment of new key executives and board members can introduce uncertainty regarding strategic direction and operational execution.
Key Players & Entities
- Cingulate Inc. (company) — Registrant
- Dr. David M. Bear (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Dr. Robert J. T. Miller (person) — Appointed Chief Scientific Officer and elected to Board of Directors
- September 9, 2024 (date) — Effective date of appointments
FAQ
What are the specific responsibilities of the new Chief Medical Officer and Chief Scientific Officer?
The filing states their appointments but does not detail specific responsibilities beyond their titles.
What is the background of Dr. David M. Bear?
The filing does not provide biographical details or background information for Dr. Bear.
What is the background of Dr. Robert J. T. Miller?
The filing does not provide biographical details or background information for Dr. Miller.
Are there any immediate strategic changes expected due to these appointments?
The filing does not explicitly state any immediate strategic changes, but the appointments are effective immediately.
What is Cingulate Inc.'s primary business?
Cingulate Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 748 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-09-12 08:30:28
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar
- $503,000 — Shane Schaffer's annual base salary of $503,000, Chief Operating Officer Laurie Myer's
- $424,000 — cer Laurie Myer's annual base salary of $424,000 and Chief Financial Officer Jennifer Ca
- $350,000 — nnifer Callahan's annual base salary of $350,000. These salaries had previously been red
- $1.45 million — e cash savings to date of approximately $1.45 million. On September 12, 2024, the Company a
- $10 million — Additionally, Cingulate has raised over $10 million in additional capital since the middle
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex99-1.htm (EX-99.1) — 18KB
- 0001493152-24-035960.txt ( ) — 287KB
- cing-20240909.xsd (EX-101.SCH) — 4KB
- cing-20240909_def.xml (EX-101.DEF) — 29KB
- cing-20240909_lab.xml (EX-101.LAB) — 36KB
- cing-20240909_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CINGULATE INC. Dated: September 12, 2024 By: /s/ Shane J. Schaffer Name: Shane J. Schaffer Title: Chief Executive Officer